If You Ran Abbott, What Would You Do?
Today’s big story: Could Anthropic Stock Fall 25%?
If you ran Abbott Laboratories (ABT), you would start with how little of each sale it keeps as profit. The business is growing, with sales rising 10.0% to $48.2 billion over the past twelve months. The stock is down 17.7% over the past year, including dividends, while the S&P 500 gained 11.0%.
Abbott is down 17.7% in a year, and that hurts most when it is one of the biggest holdings in your savings. Getting out of shares you bought long ago can also mean handing a big slice to taxes. In a free 30-minute review, our partner advisory firm can show you ways to limit your loss if the stock falls further and to sell with a smaller tax bill. Book the free review.
Including dividends, Abbott stock lost 9.7% over five years, while the S&P 500 returned 69.3%. Imagine you were handed the keys on Monday. So how much more profit could Abbott keep from its sales, and what goal would you set?

You Would Start With Abbott’s Operating Margin
Abbott kept 13.8% of its sales as operating profit over the past twelve months, as reported. The median of five large rivals, including Medtronic and Danaher, kept 20.4%. The gap stands at 6.6 percentage points. Applied to $48.2 billion of sales, that difference comes to about $3.18 billion of operating profit a year.
Abbott’s own past gives a target it has already hit. The company kept 20.0% five years earlier, and getting back there would be worth about $2.99 billion a year. The margin was lower still in the September 2026 quarter, sitting at 10.4%. So your first goal would be to win back the margin Abbott earned five years ago.
Medical Devices Grew Fastest At Abbott In 2025
Medical Devices is the part of Abbott that works best. The unit sold $21.4 billion in fiscal 2025, accounting for close to half of company revenue. It grew 12.6%, expanding faster than any other Abbott segment.
Its devices are still finding wider use. On the October 21, 2026 call, management said rhythm management sales grew 10% in the third quarter on wider use of AVEIR pacemakers. That is the part of Abbott you would build on.
Abbott Lowered Its Sales Growth Forecast For 2026
On October 21, Abbott cut its forecast for 2026 comparable sales growth to 6.0%, from 7.0% in July. Comparable growth is a different measure from reported growth. In the third quarter, reported sales grew 14.5%, while comparable sales grew 7.0%. Reported sales include Exact Sciences, a business Abbott added. Management named two businesses behind the cut, electrophysiology and diabetes. It said neither marks a permanent change in growth.
Diabetes matters most for your margin goal. Abbott expects diabetes growth in the low to mid single digits for the next few quarters. One reason is that CMS, which runs Medicare, has not yet widened payment for glucose monitors to more type 2 patients. Another is price competition abroad, where Abbott plans to cut prices to keep its market share.
Those price cuts work against the margin you want to raise. Management said Abbott’s cost programs will offset that hit.
Keep Abbott’s Dividend, But Pay Down Its Debt
Abbott produced $6.76 billion of free cash flow over the past twelve months. The business covered its payouts from its own cash, paying $4.32 billion in dividends and $1.54 billion in buybacks.
Debt is the harder call. Total debt reached $31.2 billion, up from $18.4 billion five years earlier. That is 17.2% of Abbott’s market value, below 20.3% for the S&P 500. But debt has climbed sharply in five years, so you would pay it down before buying back more stock.
The planned split of the nutrition business, expected by the end of 2027, helps a little. Management expects Abbott without nutrition to have an operating margin about one percentage point higher. That would be a start on the margin goal, not the whole of it.
At $104.48, Abbott stock trades at 38.5 times its last twelve months of earnings, compared to 21.5 for the S&P 500. That multiple suggests buyers are betting that Abbott’s profit margin recovers. Abbott is expected to report in January 2027, and management said it will probably give its 2027 guidance then.
Even a growing business like Abbott can trail the market for five years. Spreading your money across many quality leaders, not one, means a single company’s slow repair does not decide your whole result.
Why Own One Leader When You Can Own 30?
If you like finding quality companies like Abbott Laboratories, the Trefis High Quality (HQ) Portfolio holds 30 of them in equal weight, and has returned more than 105% since its September 2020 launch. You’re welcome to look inside.
Spot an error or want more like this? Tell us in 10 seconds.